Preferences for health outcomes associated with Group A Streptococcal disease and vaccination

BACKGROUND: A 26-valent Group A Streptococcus (GAS) vaccine candidate has been developed that may provide protection against pharyngitis, invasive disease and rheumatic fever. However, recommendations for the use of a new vaccine must be informed by a range of considerations, including parents'...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Grace M, Salomon, Joshua A, Gay, Charlene, Hammitt, James K
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848145/
https://www.ncbi.nlm.nih.gov/pubmed/20226042
http://dx.doi.org/10.1186/1477-7525-8-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848145/
https://www.ncbi.nlm.nih.gov/pubmed/20226042
http://dx.doi.org/10.1186/1477-7525-8-28

Ejemplares similares